Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
EVMN
Strong SellSinkerEvommune, Inc. · Healthcare · United States · $480M · Avg Vol: $6M/d
COMPANY DESCRIPTION
Evommune, Inc. is a clinical-stage biotechnology company dedicated to developing novel therapies for chronic inflammatory and autoimmune diseases. The company's pipeline targets key immunological pathways, utilizing small molecule inhibitors to address unmet medical needs in dermatology and immunology. Its competitive edge lies in its proprietary drug discovery platform and a leadership team with a proven track record of developing blockbuster immunology drugs.
FINANCIAL SUMMARY (USD)
| Year | 2024 | 2025 | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|
| Revenue | — | 13.0M | 10.0M | 0.6M | 0.8M | -75.5% |
| EPS | -4.27 | -11.22 | -11.82 | -2.79 | -3.24 | — |
| Shares | — | 31.5M | 36.3M | — | — | — |
| Debt | 1.0M | 1.7M | 8.6M | — | — | — |
| Equity | — | 205.6M | — | — | — | — |
| Op CF | — | -76.4M | -74.2M | — | — | — |
| Inv CF | — | -115.3M | — | — | — | — |
| Fin CF | — | 220.8M | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of EVMN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| EVMN | Evommune, Inc.(you) | $480M | 8 | Strong Sell |
| KYTX | Kyverna Therapeutics, Inc. | $518M | 7 | Strong Sell |
| BLSM | BlossomHill Therapeutics, Inc. | $569M | 7 | Strong Sell |
| VOGX | Vogenx, Inc. | $504M | 4 | Strong Sell |
| LXEO | Lexeo Therapeutics, Inc. | $399M | 7 | Strong Sell |
| CMPX | Compass Therapeutics, Inc. | $432M | 5 | Strong Sell |
| CABA | Cabaletta Bio, Inc. | $529M | 11 | Strong Sell |
| SPRY | ARS Pharmaceuticals, Inc. | $586M | 6 | Strong Sell |
| RCKT | Rocket Pharmaceuticals, Inc. | $424M | 11 | Strong Sell |
| UPB | Upstream Bio, Inc. | $366M | 8 | Strong Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.1%